Avita Medical (RCEL) said late Tuesday it now expects Q4 commercial revenue of about $18.4 million, below its prior outlook range of $22.3 million to $24.3 million.
Full-year 2024 commercial revenue is now pegged at roughly $64.3 million, down from its previous range of $68 million to $70 million.
For 2025, the company expects commercial revenue between $100 million and $106 million. Avita said it now expects to achieve cash flow break-even and GAAP profitability in Q4 2025, instead the previously expected Q3 2025.
The company's shares were down more than 8% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.